EMBC
Embecta Corp.
$5.23
-0.24
(-4.39%)
Mkt Cap
310.28M
Volume
1,117,801
52W Range
2.77-15.55
Sector
Healthcare
Beta
0.79
EPS (TTM)
1.49 USD
P/E Ratio
3.51
Revenue (TTM)
1.02B USD
Rev Growth (5Y)
-0.1%
EPS Growth (5Y)
-26.2%
Company Description
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.08B | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Net Income | 95.40M | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| EPS | 1.64 | 1.34 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| Free Cash Flow | 182.40M | 19.90M | 41.20M | 388.20M | 417.00M | 456.60M | 436.00M |
| FCF / Share | 3.13 | 0.34 | 0.72 | 6.80 | 7.34 | 8.01 | 7.65 |
| Operating CF | 191.70M | 35.70M | 67.70M | 412.20M | 456.00M | 498.50M | 505.00M |
| Total Assets | 1.09B | 1.29B | 1.21B | 1.09B | 788.00M | 738.00M | 745.00M |
| Total Debt | 1.43B | 1.61B | 1.64B | 1.64B | 4.10M | 0 | 0 |
| Cash & Equiv | 225.50M | 267.50M | 326.30M | 330.90M | 0 | 0 | 0 |
| Book Value | (651.20M) | (738.30M) | (821.70M) | (891.40M) | 594.00M | 572.00M | 577.00M |
| Return on Equity | N/A | N/A | N/A | N/A | 0.70 | 0.75 | 0.75 |
| Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 271.70M | 221.80M | 261.20M | 264.00M | 295.50M | 259.00M | 261.90M | 286.10M | 272.50M | 287.20M | 277.30M | 281.90M |
| Net Income | 21.10M | (4.10M) | 44.10M | 26.40M | 45.50M | 23.50M | (700,000) | 14.60M | 14.70M | 28.90M | 20.10M | 6.00M |
| EPS | 0.36 | -0.07 | 0.75 | 0.45 | 0.78 | 0.40 | -0.01 | 0.25 | 0.25 | 0.50 | 0.35 | 0.10 |
| Free Cash Flow | 40.70M | 30.60M | 16.60M | 76.70M | 80.80M | 31.70M | (6.80M) | 26.60M | (11.80M) | 20.90M | (15.80M) | 20.40M |
| FCF / Share | 0.70 | 0.52 | 0.28 | 1.31 | 1.38 | 0.55 | -0.12 | 0.46 | -0.20 | 0.36 | -0.27 | 0.36 |
| Operating CF | 41.80M | 31.10M | 17.20M | 84.00M | 81.20M | 31.80M | (5.30M) | 26.60M | (2.10M) | 24.30M | (13.10M) | 29.60M |
| Total Assets | 1.27B | 1.03B | 1.06B | 1.09B | 1.16B | 1.12B | 1.15B | 1.29B | 1.27B | 1.20B | 1.22B | 1.21B |
| Total Debt | 1.50B | 1.36B | 1.39B | 1.43B | 1.50B | 1.55B | 1.58B | 1.61B | 1.65B | 1.66B | 1.64B | 1.64B |
| Cash & Equiv | 214.70M | 184.90M | 201.30M | 225.50M | 230.60M | 209.30M | 210.00M | 267.50M | 275.10M | 299.80M | 298.70M | 326.30M |
| Book Value | (612.70M) | (626.10M) | (613.10M) | (651.20M) | (669.60M) | (736.20M) | (768.80M) | (738.30M) | (763.70M) | (769.60M) | (793.50M) | (821.70M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EMBC News
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
EMBC Court News: Embecta Securities Fraud Class Action Filed After Insulin Pen Issues and 57% Stock Drop – Contact BFA Law Before August 17
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC
EMBC DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – EMBC